HN Summary
• Oncology pharmacists improve safety, outcomes, and patient experience across cancer care.
• They help manage rising drug costs and complex treatments through evidence-based prescribing and system stewardship.
• Their role enhances efficiency and care coordination, supporting better access and sustainable cancer care.
Oncology pharmacists in Canada are delivering critical value across cancer care settings by improving safety, enhancing treatment optimization, and helping steward rapidly escalating oncology drug budgets. National analyses show that oncology medicines have nearly tripled in cost over the past decade—from $1.4 billion in 2010 to $3.9 billion in 2019—making strategic medication management essential for system sustainability.
As cancer therapies shift toward increasingly high-cost and complex regimens, oncology pharmacists ensure evidence-based prescribing, reduce medication related harm, and support smarter use of limited resources. Their contributions also meaningfully improve the patient experience: pharmacist-led oral anticancer therapy programs in Canada have achieved patient satisfaction scores as high as 9.6/10, while increasing clinic capacity and allowing pharmacists to focus on higher value clinical interventions.
Through leadership in care coordination, safety checks, education, and system level optimization, oncology pharmacists are uniquely positioned to help Canadian health systems deliver high-quality, cost-effective cancer care amid rising demand and tightening budgets.
Addressing cost and complexity in cancer care
Cancer pharmacotherapy has rapidly evolved, with targeted agents, immunotherapies, and complex combination regimens reshaping standard practice—and drug budgets. As expenditures rise, oncology pharmacists play a central role in formulary stewardship, pathway alignment, and clinical verification that ensure the right therapy is used for the right patient at the right time.
By embedding evidence review and toxicity risk mitigation into prescribing and monitoring workflows, they reduce avoidable waste and downstream costs related to adverse events or suboptimal therapy selection—imperatives in a landscape where drug costs have nearly tripled within a decade.
Improving outcomes through pharmacist led oncology services
Oncology pharmacists strengthen patient safety across the continuum—from regimen verification and drug–drug interaction checks to proactive monitoring of toxicity and adherence, especially for oral anticancer therapies (OACT). Canadian programs led by pharmacists have reported patient satisfaction scores up to 9.6/10, reflecting clearer education, timely access to medication expertise, and reliable follow-up. These models also increase clinic capacity, enabling pharmacists to redirect time toward complex clinical interventions such as dose adjustments, supportive care optimization, and symptom management—activities closely tied to fewer treatment interruptions and better tolerance of therapy.
Enhancing efficiency, access, and patient experience
As cancer incidence and treatment complexity grow, pharmacy integration helps clinics function more efficiently. Oncology pharmacists streamline care coordination, standardize safety checks, and coach patients on self-management for OACT and supportive therapies. The result is a better experience for patients and families—clearer expectations, faster answers to medication questions, and more reliable escalation pathways for side effects—while clinics benefit from optimized throughput and workload distribution across the interprofessional team. These efficiencies are essential to maintaining quality in the face of constrained resources and rising demand.
System stewardship and safety infrastructure
Beyond direct patient care, oncology pharmacists contribute to policy, pathways, and quality improvement initiatives that scale safety and value across institutions and regions. They champion standardized order sets, independent doublechecks for high alert medications, and medication reconciliation at key transition points—each reducing preventable harm. Their stewardship lens extends to biosimilar adoption, wastage reduction strategies (e.g., vial sharing protocols where appropriate), and alignment with national guidance, ensuring that investments in novel therapies translate into measurable improvements in outcomes and system sustainability.
Leadership in practice: Anjie Yang, BScPhm(Hons), MHI
A leading example of oncology pharmacy practice in Canada is Anjie Yang, an oncology pharmacist at the University Health Network (UHN), home to the Princess Margaret Cancer Centre. Her practice spans acute care oncology, malignant hematology, and both autologous and allogeneic bone marrow transplant. She has also extensively contributed to oncology clinical trials, helping establish and oversee operations for more than 120 solid tumour and transplant studies in one of the country’s most advanced oncology settings.
Anjie is also a key leader within CSHP’s Oncology Community of Practice, where rapid advancements in cancer therapy make collaboration essential. As chair, she champions the exchange of knowledge and clinical insights, fosters discussion on safety and stewardship challenges, and supports colleagues across Canada in navigating the ever-changing complexities of modern cancer care.
“The landscape has never been more exciting, with new therapeutic pathways and medications emerging constantly,” Anjie says, “this also brings new challenges and complexities, and the exchange of ideas is crucial in generating solutions in managing them.”
The integration of frontline oncology practice with national professional leadership illustrates how CSHP’s Communities of Practice amplify local expertise—supporting consistent, high-quality oncology pharmacy care and collective solutions to system level challenges in cancer treatment.